Shopping Cart
- Remove All
- Your shopping cart is currently empty
Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor. Laflunimus is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $247 | 6-8 weeks | |
25 mg | $766 | 6-8 weeks | |
50 mg | $996 | 6-8 weeks | |
100 mg | $1,490 | 6-8 weeks | |
1 mL x 10 mM (in DMSO) | $272 | 6-8 weeks |
Description | Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor. Laflunimus is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). |
In vitro | Laflunimus inhibits LPS-induced kappa light-chain cell surface expression on 70Z/3 cells, a property also reversed by uridine. Laflunimus is more potent than A77 1726 as an inhibitor of PGHS in guinea pig polymorphonuclear leukocytes (IC50= 415 and 4400 nM, respectively) and on isolated ovine PGHS-1 (IC50=64 and 742 μM) and PGHS-2 (IC50=100 and 2766 μM).Ig secretion from mouse splenocytes was induced by lipopolysaccharide (LPS) for 5 days.?Laflunimus inhibited the secretion of IgM and IgG with IC50 values of 2.5 and 2 μM , respectively.?Adding Uridine (50 μ M) increased these values to 70 and 60 μ M, respectively. |
In vivo | HR325?inhibits the secondary anti-sheep red blood cell (SRBC) antibody response with ID50 values of 38 mg/kg. |
Alias | HR325 |
Molecular Weight | 310.27 |
Formula | C15H13F3N2O2 |
Cas No. | 147076-36-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.